Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR-Reference-Cited by-同舟云学术

Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR

Published:2021-07-24 Issue:1 Volume:36 Page:292-295
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kim Sena^ORCID,Ashami Kidist,Lim Sora,Staser Karl,Vij Kiran,Santhanam Srikanth,Ritchey Julie,Peterson Sarah,Gao Feng,Ciorba Matthew A.^ORCID,Cooper Matthew L.,DiPersio John F.^ORCID,Choi Jaebok^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01360-9.pdf

Reference15 articles.

1. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340–52.

2. Choi J, Ziga ED, Ritchey J, Collins L, Prior JL, Cooper ML, et al. IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD. Blood. 2012;120:4093–103.

3. Choi J, Cooper ML, Alahmari B, Ritchey J, Collins L, Holt M, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014;9:e109799.

4. Ashami K, DiPersio JF, Choi J. Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD. Oncotarget. 2018;9:35721–2.

5. Choi J, Cooper ML, Staser K, Ashami K, Vij KR, Wang B, et al. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia. 2018;32:2483–94.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CS12192: A novel selective and potent JAK3 inhibitor mitigates acute graft-versus-host disease in bone marrow transplantation;Transplant Immunology;2024-08

2. IRG1/Itaconate inhibits proliferation and promotes apoptosis of CD69+CD103+CD8+ tissue-resident memory T cells in autoimmune hepatitis by regulating the JAK3/STAT3/P53 signalling pathway;Apoptosis;2024-04-19

3. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model;Molecules;2024-04-16

4. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease;Frontiers in Immunology;2024-02-06

5. Ruxolitinib attenuates acute rejection and can serve as an immune induction therapy in heart transplantation;Clinical Immunology;2023-12